Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a
health and wellness company specializing in the formulation of a suite of
medicinal mushroom health products, as well as novel delivery platforms for the
pharmaceutical and nutraceutical industries, today announced the appointment of
Dr. Joseph Gabriele, a molecular pharmacologist specializing in signal
transduction within the central nervous system, to its Special Advisory
Committee. According to the update, Dr. Gabriele, PhD, specializes in the areas
of molecular pharmacology, transdermal delivery and formulation chemistry with
pharmaceutical, natural molecules and will champion the company’s development
and commercialization of rapid onset treatments capable of improving health
outcomes. “Dr. Gabriele’s established research credentials, entrepreneurial
nature and relentless pursuit of medical innovation represents the desired
skill sets that Champignon needs as we accelerate our accession into the
psychedelic medicine arena,” Champignon Brands CEO Gareth Birdsall said in the
news release. “The appointment of Dr. Gabriele equips us with both a celebrated
medical researcher, as well as a seasoned CPG formulation specialist, which
will allow for the continued development of our mushroom-infused health
products, novel delivery systems and eventual drug discovery initiatives.
Champignon Brands is set to emerge as an impact investment that may not only
change people’s lives but may also revolutionize the face of medicine as we
know it today.”
To view the full press release, visit http://ibn.fm/GVLMY
About Champignon Brands Inc.
Champignon Brands Inc. (CSE: SHRM) is a research driven
company specializing in the formulation of a suite of medicinal mushrooms
health products, as well as novel ketamine, anesthetics and adaptogenic
delivery platforms for the nutritional, wellness and alternative medicine
industries. Via its vertically integrated alternative medicine product range,
Champignon is pursuing the development and commercialization of rapid onset
treatments capable of improving health outcomes for indications such as
depression and Post Traumatic Stress Disorder (“PTSD”), as well as substance
and alcohol use disorders. Champignon continues to be inspired by
sustainability, as its medicinal mushroom infused SKUs are organic, non-GMO and
vegan certified. For more information, visit the company’s website at www.Champignonbrands.com.
NOTE TO INVESTORS: The latest news and updates
relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment